Pharmacokinetic profiles of antifungal drugs during extracorporeal membrane oxygenation life support
10.3760/cma.j.cn121430-20210816-01186
- VernacularTitle:体外膜肺氧合生命支持期间抗真菌药物的药代动力学特征
- Author:
Dengyun FAN
1
;
Shan LI
;
Yixin LIU
;
Feifei REN
;
Zhenzhen YANG
;
Xikun WU
;
Yingchao MA
;
Zhiqing ZHANG
;
Yakun ZHANG
Author Information
1. 河北医科大学第二医院药学部，石家庄 050000
- Keywords:
Antifungal drug;
Pharmacokinetics;
Extracorporeal membrane oxygenation;
Therapeutic drug monitoring
- From:
Chinese Critical Care Medicine
2022;34(1):100-104
- CountryChina
- Language:Chinese
-
Abstract:
Extracorporeal membrane oxygenation (ECMO), a kind of life support technology that can replace lung and heart function, is widely used in critical respiratory and circulatory exhaustion. Because of the serious diseases and the use of interventional catheters, patients receiving ECMO life support are often administrated with broad-spectrum antimicrobial agents, which increase the risk of fungal infection. Fungal infection during ECMO can increase mortality. How to effectively control fungal infection is a thorny problem faced by clinicians. During the treatment of ECMO, the patient's physiological status, ECMO oxygenation membrane, circulation pipeline and other factors may change the pharmacokinetic profiles of antifungal drugs, thereby affect the clinical efficacy of drugs. This artical reviews the pharmacokinetic characteristics of antifungal drugs during ECMO support, in order to provide references for clinical antifungal treatment.
